Kairos Pharma annual return on equity
2024
2025
Kairos Pharma Return on Equity (ROE) Growth & History (KAPA)
Kairos Pharma's return on equity was −97.99% for fiscal 2025.
View full Kairos Pharma company overviewKairos Pharma annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −97.99% | +94.96 pp |
| 2024 | 2024-12-31 | −192.96% | — |
Kairos Pharma quarterly return on equity
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −29.21% | −7.55 pp |
| Q1 2026 | 2026-03-31 | −28.39% | −7.19 pp |
| Q4 2025 | 2025-12-31 | −19.49% | +4.68 pp |
| Q3 2025 | 2025-09-30 | −20.47% | +146.52 pp |
| Q2 2025 | 2025-06-30 | −21.66% | — |
| Q1 2025 | 2025-03-31 | −21.20% | — |
| Q4 2024 | 2024-12-31 | −24.17% | — |
| Q3 2024 | 2024-09-30 | −166.99% | — |
Kairos Pharma return on equity trends
Between the periods ended 2024-12-31 and 2025-12-31, Kairos Pharma's return on equity increased from −192.96% to −97.99%, a change of +94.96 percentage points. The latest reported quarter, Q2 2026, shows −29.21%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Kairos Pharma source filings ↗